Specific Populations
    Retatrutide

    Retatrutide and Fertility

    Retatrutide and fertility is a critical topic for men and women of reproductive age considering weight loss treatment. While retatrutide itself must be discontinued before pregnancy, the weight loss it produces can dramatically improve fertility in both sexes. Obesity is one of the most common reversible causes of infertility, and the 24% weight loss seen in Phase 2 trials (Jastreboff et al., NEJM 2023) could restore reproductive function in many patients who struggle to conceive.

    Published: April 3, 202612 min read

    The relationship between obesity and infertility is well-established and bidirectional. Excess body weight disrupts reproductive hormones, impairs gamete quality, reduces conception rates, and increases pregnancy complications. For couples struggling with infertility, weight loss is often one of the most effective and underutilized interventions. GLP-1 medications like retatrutide offer a path to the significant weight loss needed to restore fertility -- but they come with important timing and safety considerations that every patient must understand.

    Critical Reproductive Safety Notice

    All GLP-1 medications, including retatrutide, must be discontinued before pregnancy. Retatrutide is not FDA-approved for any indication and has not been studied in pregnancy. Use reliable contraception during treatment. Discontinue at least 2 months before planned conception. If you become pregnant during treatment, stop the medication immediately and contact your healthcare provider. Compounded semaglutide ($99/mo) and tirzepatide ($125/mo) are available now.

    Weight Loss and Female Fertility

    Obesity impairs female fertility through multiple mechanisms. Excess adipose tissue disrupts the hypothalamic-pituitary-ovarian axis, leading to irregular or absent ovulation. Elevated insulin and androgens (particularly in PCOS) create an inhospitable hormonal environment for conception. Obesity reduces egg quality and endometrial receptivity. And even with conception, obese women face higher rates of miscarriage, gestational diabetes, preeclampsia, and birth complications.

    Weight loss of 5-10% can restore ovulatory cycles in many women, reduce miscarriage risk, and improve IVF success rates. The 24% weight loss with retatrutide would be expected to provide dramatic fertility improvement, potentially resolving obesity-related infertility entirely in many cases.

    Weight Loss and Male Fertility

    Male obesity impairs fertility through reduced testosterone (via aromatization of testosterone to estrogen in fat tissue), impaired sperm quality (reduced count, motility, and morphology), erectile dysfunction and reduced sexual frequency, and increased scrotal temperature from excess fat. Weight loss reverses most of these effects, with testosterone recovery being particularly important. Men do not need to discontinue GLP-1 medications for conception, as these drugs have not shown direct effects on sperm or male reproductive organs.

    Treatment Timing and Planning

    • Start treatment early: If planning pregnancy in 6-12 months, start weight loss medication now to achieve significant weight loss before discontinuation.
    • Discontinue 2+ months before conception: This allows medication clearance and metabolic stabilization.
    • Use reliable contraception during treatment: Weight loss can restore fertility unexpectedly -- do not rely on previous anovulation as contraception.
    • Consider non-oral contraception: GLP-1 medications may affect oral contraceptive absorption.
    • Maintain healthy habits: The lifestyle habits established during treatment (nutrition, exercise) help maintain weight and fertility after medication stops.

    Plan Your Path to Parenthood

    Compounded semaglutide ($99/mo) and compounded tirzepatide ($125/mo) can help you achieve a healthier weight before conception. Our physicians understand reproductive planning considerations and can help time treatment appropriately.

    Medical Disclaimer

    This article is for informational purposes only and does not constitute medical advice. Retatrutide is not FDA-approved for any indication and has not been studied in pregnancy. All GLP-1 medications must be discontinued before pregnancy. Fertility treatment should be supervised by a reproductive endocrinologist. Do not start or stop any medication without consulting your healthcare provider.

    Improve Your Fertility Through Weight Management

    Compounded semaglutide from $99/mo. Compounded tirzepatide from $125/mo. Physician-supervised care.

    View Treatment Options

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for retatrutide?

    Peer-reviewed evidence: Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

    Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. — Jastreboff et al. Phase 2 trial, NEJM 2023
    Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. — Rosenstock et al. Phase 2 T2D trial, Lancet 2023

    Key Takeaways

    • Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023)
    • Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. (Source: Rosenstock et al. Phase 2 T2D trial, Lancet 2023)
    • Retatrutide is investigational and not FDA-approved as of publication. Trial findings reported here are from Phase 2 / Phase 3 studies in peer-reviewed sources cited below.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: December 21, 2025

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    Amy KeithFacebook
    I'm on my 4th week. No side effects. 5 lb loss which seems slow to me. Food noise is much better. We shall see!

    Outcome: 5 lbs lost in 4 weeks; no side effects; food noise reduced

    Lynn SchweitzerFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2301972
    2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet.Read StudyDOI: 10.1016/S0140-6736(23)01053-X
    3. ClinicalTrials.gov (2024). A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1) — NCT05929066. ClinicalTrials.gov.Read Study
    4. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    5. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    6. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Buy compounded semaglutide online in Texas for $99/month. Learn about Texas telehealth laws, compounding pharmacy access, and how to start affordable GLP-1 weight loss treatment.

    Complete guide to semaglutide 1.7mg dosing. Learn about expected weight loss results, side effects at this higher dose, and how to decide between staying at 1.7mg or advancing to 2.4mg.

    Retatrutide and alcohol: practical guide to drinking during GLP-1 treatment. Learn about safety considerations, weight loss impact, why many patients naturally reduce alcohol, and the safest choices i

    Complete guide to combining semaglutide and metformin. Learn about safety, synergistic benefits for diabetes and weight loss, GI side effect management, and dose adjustment considerations.

    Start your GLP-1 journey — from $99/mo

    Get Started